Fluidx Medical Technology closes financing for embolic platform
What's the deal? Fluidx Medical TechnologyDealroom has a profile for this one. Try Dealroom →, a Salt Lake City-based developer of embolic technologies, has closed a round of financing to fund development and growth. The company did not disclose the amount or its backers. It plans to commercialise its GPX and ULTRA embolic devices and advance its IMPASS neurovascular platform.
What does Fluidx do? It develops embolic gels that block blood vessels — from the smallest to the largest — to treat a range of conditions. Its pipeline spans peripheral vascular, interventional oncology and neurovascular embolisation.
Why now? The financing follows completion of the GPX IDE clinical trial and continued work on ULTRA. Fresh capital will support manufacturing and commercial readiness for GPX and ULTRA while accelerating clinical activity on IMPASS after preclinical results were presented at the Society of NeuroInterventional SurgeryDealroom has a profile for this one. Try Dealroom → Annual Meeting.
What's the endgame? Fluidx aims to build a broad portfolio of embolic solutions across peripheral and neurovascular interventions. The money will expand manufacturing and commercial readiness while advancing clinical activity on IMPASS.
What sets it apart? Unlike rival embolic devices, Fluidx's gels avoid toxic dimethyl sulfoxide, do not glue catheters into the body, and need no special delivery systems or preparation stations. All three products remain under development and lack marketing clearance in any market.
“This financing is an important milestone for Fluidx as we continue executing on our mission to redefine embolisation with technologies that are simple to use and highly controllable,” said chief executive officer Libble GinsterDealroom has a profile for this one. Try Dealroom →.
The signal: The raise underscores interest in minimally invasive vascular tools that reduce procedural complexity. For Fluidx, the test now is turning clinical progress into regulatory clearances and commercial traction.
Read more: EIN Presswire
Image credit: NavyMedicine
